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Purpose: This study reports our midterm results with arteriovenous axillary loop grafts (AVALG) and evaluates their role
in construction of vascular access for patients on chronic hemodialysis.
Methods: The clinical data of 27 patients who underwent construction of an AVALG for hemodialysis access at our
institution between July 2002 and December 2006 were analyzed retrospectively. Outcome measures included graft
patency, the complication rate, and the frequency and morbidity of secondary procedures after AVALG creation. The
Kaplan-Meier method was used to calculate the primary and secondary patency curves.
Results: AVALG was constructed as the first access procedure in eight patients: five patients with no suitable vein to
construct an adequate angioaccess on the upper limbs, and three patients with elbow and forearm arteritis. The 19 other
patients had all had two to five failed prior vascular accesses leading to exhaustion of venous access sites on the upper
extremities (18 cases), or a steal syndrome (one case). No postoperative death occurred, but four patients died of causes
unrelated to the intervention between the second and the tenth postoperative months. The mean follow-up was 15
months (range, 2-48 months). The primary patency rate at 12 months and the secondary patency rate at 18 months were
51% and 80%, respectively. Infection (three cases), thrombosis (seven cases), and stenosis of the outflow vein (two cases)
were the main complications, occurring in 10 of the 27 patients (41%). Twelve secondary procedures were performed in
these 10 patients with little additional morbidity. Five of the 27 patients developed irreversible AVALG occlusion leading
to access loss: two patients with concomitant graft infection and three patients with a history of subclavian vein
catheterization.
Conclusion: AVALG may represent a supplementary option for chronic hemodialysis patients with vascular steal or
inadequate upper extremity venous access sites. ( J Vasc Surg 2008;47:138-43.)The number of patients with end-stage renal disease
(ESRD) requiring hemodialysis is constantly rising world-
wide.1 In Europe, over 25% of all hospital admissions for
ESRD are for the construction or maintenance of a patent
vascular hemodialysis access.2 Arteriovenous fistulas con-
structed from autogenous upper extremity veins are the
vascular access of choice as they offer the best patency and
lowest complication rates.3 While the life expectancy of
patients on chronic dialysis continues to lengthen,1,4 the
durability of these vascular accesses is limited. Repeat fistula
construction at different levels of the upper extremity
(wrist, forearm, upper arm) is often necessary and can
ultimately result in exhaustion of autogenous vascular ac-
cess sites. Use of a synthetic prosthesis to construct on the
upper arm an arteriovenous brachial-axillary graft or on the
forearm a brachial-brachial loop graft is currently the rec-
ommended treatment alternative for patients who have
exhausted all native fistulas access options.3,5 However,
such grafts have lower patency rates and shorter lifetimes
than autogenous arteriovenous fistulas.3 Recourse to lower
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138extremity veins6 or indwelling central venous catheters7,8
often becomes necessary for the survival of patients on
chronic hemodialysis. However, the morbidity of these
procedures remains elevated. Construction of a loop graft
from one axillary artery to the ipsilateral axillary vein may
represent a supplementary alternative for these patients.9
To our knowledge, no series dealing solely with these
arteriovenous axillary loop grafts (AVALG) has been pub-
lished to date. The purpose of this study was to report our
midterm results with AVALG and to evaluate their role in
the creation of vascular accesses for patients requiring
chronic hemodialysis.
MATERIAL AND METHODS
Between July 2002 and December 2006, 435 consec-
utive procedures for creation of a hemodialysis vascular
access were performed in our vascular surgery department.
Demographic data for all patients and the types of access
constructed were recorded in a computerized database. For
study purposes, all patients who had AVALG construction
during this period were identified and their charts were
reviewed. Themain reason for selection of an arteriovenous
axillary loop configuration was mentioned in the individual
operative reports. Demographic data, cardiovascular risk
factors, and the cause of ESRD were noted in each clinical
file. The number, the locations, and the type of any previ-
ous vascular accesses were also recorded for each patient.
All technical details, including AVALG construction, the
duration of the procedure, and the material used were also
noted.
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surgeons in our department using a standard protocol. All
patients underwent preoperative arterial Doppler ultrasound
to rule out a proximal lesion on the axillary-subclavian arterial
axis. Likewise, venous Doppler ultrasound was performed for
all patients to rule out stenosis or occlusion of the homolateral
subclavian vein. Phlebography was performed in selected pa-
tients to rule out a central venous lesion. All patients were
operated under general anesthesia in dorsal decubitus with
the upper extremity abducted on the operated side. A single
dose of cefazolin (2000 mg) was administered to every
patient just prior the skin incision. Fig 1 presents the usual
configuration of AVALG performed in our department.
For all patients, a 7-cm long transverse incision was made 2
cm below the clavicle. A loop was constructed in a subcu-
taneous tunnel, superficial to the pectoralis major muscle;
two intermediate incisions were made on either side of the
top of the loop (Fig 1). Three minutes before arterial
clamping, a bolus of 50 IU/kg of unfractionated heparin
was administered to all patients. The prosthesis consisted in
a tapered (4-7 mm diameter) polytetrafluoroethylene tube
(PTFE, Vascugraft B. BRAUN, Berlin, Germany) with a
standard, nonreinforced wall. We have used a tapered 4-7
mmPTFE tube with the 4mm tip implanted on the axillary
artery so that we could calibrate the arterial anastomosis to
avoid high flow rate problems. Conversely, the 7 mm
extremity was implanted on the axillary vein where anasto-
motic stenosis is more likely to occur. Arterial anastomosis
was always performed first. The 4-mm PTFE segment was
implanted end-to-side on the antero-superior aspect of the
axillary artery using a running polypropylene 6-0 suture.
The transpectoral graft trajectory towards the subcutane-
ous tissue was cautiously fashioned to avoid kinking. End-
Fig 1. Configuration of axillary loop grafts for hemodialysis.to-side anastomosis to the axillary vein was performed last.This anastomosis was always placed laterally to the arterial one
(Fig 1) in order to direct the arteriovenous flow clockwise, to-
wards the heart, and thus, possibly limit postoperative arm
edema.Presence of a thrill in the AVALG at unclamping was
systematically verified. The incisions were closed in two
layers with aspiration-drainage placed at the level of the
subclavian access. Postoperatively, no antiplatelet or anti-
coagulant treatment was added to the drugs the patient had
been taking before the intervention.
During follow-up, the AVALG was monitored by both
the treating nephrologists and a vascular surgeon. Clinical
examination was performed by the surgeon before hospital
discharge, after 1 and 3 months, and then every 6 months.
The nephrologists monitored blood flow in the loop graft
by Doppler ultrasound and the compression time required
for hemostasis after hemodialysis. Flow assessments by
dilution techniques were not performed because they were
not available in our dialysis referring centers during the
study period. Doppler ultrasound was performed whenever
anomalies were detected clinically (pulsatility, disappear-
ance of the thrill, upper extremity edema), in case of poor
hemodialysis performance or in case of prolongation of the
compression time required at the end of the hemodialysis.
Besides, Doppler ultrasound was systematically performed
after 3 and 6 months, then every year in the absence of any
complication. All complications, their date of onset, the
treatment administered, and the result of management
were recorded systematically. In case of permanent throm-
bosis or occlusion of the axillary loop, the alternate vascular
accesses used next for hemodialysis were noted, as was the
cause of the thrombosis or occlusion.
The main purpose of this retrospective study was to
determine the primary and secondary patency rates of
AVALG in patients on chronic hemodialysis. The second-
ary aims were evaluation of the rates of short- and midterm
complications related to subclavian loops, identification of
causes leading to permanent AVALG access loss, and as-
sessment of the frequency and morbidity of secondary
procedures in patients with AVALG.
Statistical analysis was performed with StatView software
(SAS Institute, Inc., Cary, NC; version 5.0). Nominal vari-
ables were expressed as a number and a percentage of patients.
Continuous variables were expressed as the mean standard
deviation or the range for non-Gaussian distributions. The
Kaplan-Meier method was used to calculate the primary and
secondary patency curves. Patency rates were estimated un-
reliable according to Sidawy et al10 when standard error
exceeds 10%.
RESULTS
From July 2002 to December 2006, among 435 vas-
cular accesses for hemodialysis performed in our depart-
ment, 27 AVALGwere constructed on 27 patients: 15men
and 12 women. Mean age was 73 years (51-92 years).
Hypertension, diabetes, and severe coronary artery disease
were the main comorbid factors present in 17 (63%), 8
(30%), and 8 (30%) patients, respectively. The main causes
of ESRD in this cohort are listed in the Table. These 27
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months (range, 0-95 months), and they all underwent
arterial and venous Doppler ultrasound of the upper ex-
tremities preoperatively. Phlebography was performed to
rule out central venous stenosis before AVALG construc-
tion on two patients with inconclusive Doppler findings.
None of the 27 patients had preoperative upper limb arte-
riography. The AVALG was created as the initial access site
in eight patients: five patients with no suitable vein to
construct an adequate angioaccess on the upper limbs as
evidenced by preoperative Doppler ultrasound (venous
obstruction, or multiple vein stenoses), and three patients
with elbow and forearm arteritis (severely calcified arterial
wall, arterial stenosis or arterial occlusion at Doppler exam-
ination). For the other 19 patients, a total of 38 different
hemodialysis access sites (between two and seven prior
accesses per patient) had been previously constructed and
failed, leading to exhaustion of venous access sites on the
upper extremities (18 cases) or to a steal syndrome (one
case). These patients had had: 10 brachial-cephalic fistulas,
14 brachial-axillary grafts, 4 brachial-basilic fistulas, 8 wrist
cephalic-radial fistulas, and 2 lower extremity arteriovenous
fistulas constructed using the superficial femoral vein. On
the whole, the axillary site was selected because of inade-
quate access options for venous reasons in 23 patients and
for upper extremity arteritis in three patients. In the last
patient, the loop was constructed after ligation of a homo-
lateral brachial-cephalic fistula responsible for vascular steal
syndrome with severe ischemia and several fingers necrosis.
This patient showed no signs of recurrent ischemia after
AVALG construction.
The AVALG were constructed on the right side in 24
patients and on the left side in three patients. The mean
operating time was 93 minutes (range, 60-150 minutes).
The mean flow in the graft was 1.1 l/min (range, 0.5-1.8
l/min.). The mean duration of the hospital stay was 2.6
days (range, 2-4 days). No postoperative deaths occurred,
but one 61-year-old man developed acute lung edema in
the immediate postoperative period that evolved favorably.
There was no additional operative morbidity.
No patients were lost to follow-up (mean 15 months;
range, 2-48 months). Four patients (15%) died of causes
unrelated to the intervention (two in the second month,
Table. Etiology of chronic end-stage renal disease
Cause N %
Diabetic nephropathy 7 26%
Nephroangiosclerosis 3 11%
Renal polycystosis 2 7%
Bilateral nephrectomy for cancer 2 7%
Renal agenesis with fibromyositis 1 4%
Chronic interstitial nephropathy 1 4%
Toxic nephropathy 1 4%
Monoclonal gammapathy 1 4%
Undetermined 9 33%
Total 27 100%one in the fourth month, and one in the tenth postopera-tive month). Among these four deaths, three patients died
before their loop could be used. During follow-up, 10 of
the 27 patients (41%) developed one or more complica-
tions related to their axillary loop: postanastomotic stenosis
on the outflow vein in 2 patients, thrombosis of the subcla-
vian vein downstream of the loop in 4 patients, graft
occlusion in 7 patients, and AVALG infection in 3 patients.
No case of false aneurysm was diagnosed. The primary
patency rate at 12 months was 51% (Fig. 2). Both cases of
postanastomotic stenosis of the outflow vein were revealed
by upper extremity edema associated with poor hemodial-
ysis performance. The stenosis in these two patients was
successfully treated by angioplasty of the outflow vein and
stent placement. Two of the four patients who developed
thrombosis of the downstream subclavian vein also had
prosthetic obliteration; the other two still had a patent
loop. One of these patients with a patent loop presented
with upper extremity edema; the other presented a clinical
picture of severe upper extremity venous ischemia associ-
ated with edema. Endovascular stent placement in a sub-
clavian vein of these last two patients restored patency. The
seven cases of graft occlusion were associated with throm-
bosis of the downstream subclavian vein (two cases), anas-
tomotic stenosis (three cases), or graft infection (two
cases). Neither of the two occluded grafts secondary to
thrombosis of the downstream subclavian vein was salvage-
Fig 2. Kaplan Meier curves of primary and secondary patency
rates. Standard error exceeds 10% after 12 months for primary
patency. Standard error exceeds 10% after 24months for secondary
patency.able. The anastomotic stenosis was located on the venous
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segment in one patient. Both venous segment stenoses
were successfully treated by angioplasty and stent place-
ment at the site of the venous lesion after surgical throm-
bectomy at the level of the loop. The patient with anasto-
motic stenosis of the arterial loop segment underwent
surgical thrombectomy and angioplasty without stent
placement. This was followed by early and irreversible
recurrence of thrombosis. The three cases of AVALG infec-
tion were related to needle site infection (two cases occur-
ring at 9 months and 24 months, respectively, from the
initial operation) or to operative wound infection (one
case). Of those three patients who developed AVALG
infection, the one with operative wound infection under-
went removal and replacement of the entire AVALG 2
months postoperatively using a silver-coated polyester
prosthesis (InterGard Silver, La Ciotat, France). This sec-
ond loop became occluded 3months later and could not be
salvaged. The two other patients who developed an infec-
tion were managed by replacement of the infected segment
of the PTFE graft with a silver-coated polyester prosthesis
(InterGard Silver). In one of these two patients, the poly-
ester loop was still patent after a follow-up of 36months. In
the other patient, infection recurred 3months later and was
retreated in the same manner; this new loop became per-
manently occluded 9 months after the second intervention.
In overall, 12 secondary procedures were performed on the
axillary loops of the 10 patients who developed complica-
tions. However, five patients had irreversible occlusion
leading to permanent loss of the AVALG access. The
secondary patency rate at 18 months was 80% (Fig. 2).
Among the five patients who developed permanent axillary
loop occlusion, we could note a concomitant graft infection
(two patients), a history of subclavian vein catheterization
(three patients), or an anastomotic stenosis of the arterial
loop segment (one patient). Alternate temporary hemodi-
alysis was performed on these five patients using temporary
jugular catheters (two cases) or temporary femoral cathe-
ters (three cases). In the midterm, two of those five patients
underwent placement of an indwelling Canaud catheter.
Two other patients had successful construction of another
vascular hemodialysis access: one arteriovenous brachial-
brachial loop and one arteriovenous femoral-femoral fistula
using the superficial femoral vein. Peritoneal dialysis was
instituted for the last patient.
DISCUSSION
With a 12-month primary patency rate of 51% and a
secondary patency rates of 80% at 18 months, our results
reveal that AVALG permit satisfactory hemodialysis when
constructed in selected patients. The potential limitations
of this study are those of any retrospective study without a
control group and its relative small sample size. Neverthe-
less, our secondary patency rate was markedly better than
theminimum recommended by the National Kidney Foun-
dation (70% secondary patency at 1 year5). The use of
endovascular techniques, associated in the most severe
cases with surgical thrombectomy, considerably improvesthe lifetime of AVALG used for hemodialysis with low
morbidity.
After a mean follow-up of 15 months, the majority of
axillary loop complications in our patients corresponded to
thrombosis. Anastomotic stenosis secondary to myointimal
hyperplasia, subclavian vein occlusion, or stenosis of the
outflow vein were diagnosed and corrected in most of the
patients who developed AVALG thrombosis. The differ-
ence in compliance between the vein and the prosthesis,
flow turbulence in the vein, the vascular trauma during
clamping, and the effects of high blood flow on the venous
system are among the main explanations for the frequency
of venous stenosis (anastomotic or postanastomotic) after
construction of prosthetic arteriovenous grafts.11 Creation
of an AVALG requires clamping of the axillary vein down-
stream, and vascular clamps can promote stenosis of the
venous segment of vascular hemodialysis accesses.12 How-
ever, brachial-axillary grafts, which also require axillary vein
clamping, have a lower incidence of venous stenosis.3
Oguzkurt et al reported a potential correlation between
central venous stenosis and high blood flow in vessels
accessed for hemodialysis.13 One might assume that the
proximal location of AVALG with potential consequent
high flow rate, could explain the frequency of venous
stenosis in our study. Although we cannot entirely discount
this hypothesis, flow rate was between 0.85 liter/min. and
1.3 liter/min. in our patients, and thus, did not reach the
mean 2.3 liter/min reported in Oguzkut’s article.13 Like-
wise, no high blood flow-induced heart failure was diag-
nosed in our patients, but the duration of follow-up in our
study may be insufficient to judge the potential cardiac
repercussion of AVALG. Missed central venous lesion by
preoperative Doppler ultrasound may also account for the
frequency of venous stenosis in our study population. In-
deed, phlebography or magnetic resonance angiography
(MRA) is more reliable than Doppler ultrasound for the
diagnosis of central venous lesions. In our policy we have used
Doppler ultrasound as the initial exam and rarely performed
phlebography.Wewere probablywrong and should adhere to
the guidelines by using routine phlebographyor routineMRA
before all AVALG construction. In our opinion, that could
only improve further the functional patency of AVALG and
extend its indications to patients with false negative Doppler
examination for central vein stenosis. Infection occurred in
11% of our patients, a rate only slightly higher than the 10%
judged acceptable by the National Kidney Foundation
(guideline 32).5 Nevertheless, these graft infections, mostly
related to needle site puncture, were associated with two
cases of AVALG failure and permanent loss. A strict proto-
col guaranteeing diversification of axillary loop puncture
sites might reduce the incidence of infectious complica-
tions. The 15%mortality rate at 1 year in our patients (mean
age 73 years) is consistent with the mortality rates usually
reported for elderly patients on chronic hemodialysis who
have an arteriovenous graft.4 Furthermore, no patient
death was related to the presence or construction of an
axillary loop.
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AVALG for hemodialysis access. We have preferred the
right axillary vessels rather than the left (24 vs 3) for
creating AVALG since it is more likely for the left brachio-
cephalic vein to be compressed by the innominate artery
and lead to stenosis downstream the left axillary vein under
a relatively high flow rate regimen.13,14,15 Besides, the
indications and the role of this technique for construction
and maintenance of a patent vascular hemodialysis access
have not yet been established. One of our patients, who
presented arterial ulcers of the hand, underwent successful
AVALG construction after ligation of a functional brachial-
cephalic fistula. Distal revascularization-interval ligation
(DRIL), as recommended by Schanzer et al,16 gold stan-
dard in this indication, was not possible in this patient
because of the severely septic lesions on his hand. Our
approach was, nevertheless, justified by the study data
published by Gradman and Pozrikidis, who demonstrated
improved distal perfusion with axillary-axillary arterio-
venous graft in vitro.17 As those authors stated previously,
transposing the origin of a brachial-axillary access from a
distal brachial artery to a more centrally site in the arterial
circulation could also increases flow to both the access and
the forearm as do the DRIL procedure, since flow in each
configuration (DRIL and AVALG) divides in the axilla and
each access consists of a descending and ascending limb.
Aside from this steal syndrome case, the main indica-
tions for AVALG construction in our chronic hemodialysis
patients were exhaustion of conventional upper limb vas-
cular access sites and inadequacy of upper limb veins for
construction of an autologous arteriovenous fistula or a
traditional upper extremity arteriovenous graft. Several in-
novative alternative techniques, often reflecting great cre-
ativity, have been proposed for those indications. Use of
lower extremity vessels6,18 and exotic arteriovenous graft
configurations9,19 (axillary-jugular, axillary-contralateral
axillary, axillary-femoral, or even axillary-popliteal) have
been reported, but their results remain uncertain. Bunger
et al reported acceptable primary and secondary patency
rates (90% and 93% at 6 months, respectively)20 using
axillary-axillary interarterial chest loop conduits. Huber
et al described translocation of the superficial femoral vein
to the upper extremity for creation of a brachial-axillary
graft.21 Angle and Chandra performed two-stage construc-
tion of an arteriovenous brachial-brachial fistula as the initial
surgical vascular access in some 20 patients who were starting
hemodialysis without any superficial vein suitable for autoge-
nous vascular access construction.22 On the whole, we pre-
ferred AVALG rather than any arteriovenous access involving
lower extremity vessels owing to the latter’s higher inherent
risks of sepsis, ischemia, and amputation.23,24 Likewise, in-
terarterial loops were not used because of their theoretical
risks of ischemia and distal embolization. Zanow25 and
Bunger20 reported this last complication in 5% and 3.2% of
patients with an interarterial axillary-axillary loop for hemo-
dialysis, respectively. To the best of our knowledge, the
feasibility of arteriovenous brachial-brachial fistulas was not
evaluated in chronic hemodialysis patients who had under-gone one or more earlier attempts at surgical vascular
access.
One potential limitation of axillary loops is the need for
construction under general anesthesia in patients who are
already fragile. One could consider a contraindication of
general anesthesia as a theoretical contraindication for
AVALG construction. Although various local-regional an-
esthesia techniques can be used for loop graft construction,
they were not used for any of our patients. Absolute intra-
operative patient immobility appears important during
graft anastomosis to the axillary vessels. While the fre-
quency of secondary procedures may appear elevated, such
procedures are often needed to maintain the patency of
prosthetic vascular accesses.26 Furthermore, most of these
secondary procedures were performed under local anesthe-
sia with very little additional morbidity.
The results and low postoperative morbidity of these
27 prosthetic arteriovenous axillary loops suggest that this
technique may be performed simply. A patent AVALG
permits satisfactory hemodialysis for ESRD patients after
exhaustion of traditional possibilities for upper extremity
vascular access. In case of AVALG failure, another hemo-
dialysis access can be constructed using lower extremity
vessels. Our findings also suggest that creation of an
AVALG does not compromise alternate placement of an
indwelling central venous catheter in the ipsilateral jugular
vein.
CONCLUSION
This study demonstrated that construction of AVALG
is a supplementary alternative for patients on chronic he-
modialysis with inadequate upper extremity venous access
options or vascular steal. Results suggest that AVALG
construction may be preferable to lower extremity vascular
access, in particular for patients without any history of
subclavian vein catheterization or pacemaker placement.
Additional prospective studies including greater numbers
of patients may be warranted to confirm these observations.
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